Heartburn efficacy study
This article was originally published in The Tan Sheet
Out of nearly 2,000 study participants and GERD sufferers in Europe and the U.S., those who took prescribed proton pump inhibitors were more likely to have improved symptoms than those whose symptoms were undiagnosed and took OTC remedies, according to a study presented during Digestive Disease Week May 14-19 in Chicago. Roger Jones, Guy's King's and St. Thomas School of Medicine, et al., used a 100-item questionnaire to identify participants. "Of undiagnosed sufferers taking OTC medicines, 81% still suffered some symptoms compared with 68% of diagnosed patients taking prescription drugs and 69% of diagnosed patients taking PPIs," the study states. Astrazeneca, marketer of prescription Nexium, provided funding for the study...
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.